| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
After three days of treatment, W1131 (0-2 μM; 72 h) suppresses colonies and prevents AGS cell proliferation, migration, and potentiation [1]. In AGS cells, W1131 (0.1-3 μM; 24 hours) efficiently suppresses STAT3. W1131 (1 μM; 48 hours) suppresses the expression of GPX4, SLC7A11, and FTH1 and induces ferroptosis [1].
|
|---|---|
| ln Vivo |
W1131 (3 mg/kg, 10 mg/kg; i.p.; once daily for 2 weeks) suppresses tumor growth in a dose-dependent manner and is triggered in the MGC803 subcutaneous xenograft model in BALB/c-nu/nu mice
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: AGS cell Tested Concentrations: 0.1 μM, 0.3 phosphorylation [1]. μM, 1 μM and 3 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dose-dependent reduction of phosphorylated Y705-STAT3, but not STAT5, JAK2 and AKT. Immunofluorescence [1] Cell Types: AGS cell Tested Concentrations: 0.3 μM, 1 μM Incubation Duration: 12 hrs (hours) Experimental Results: Dramatically promotes lipid ROS formation and induces Fe2+ accumulation. |
| Animal Protocol |
Animal/Disease Models: MGC803 mouse subcutaneousxenograft tumor[1]
Doses: 3 mg/kg, 10 mg/kg Route of Administration: intraperitoneal (ip) injection; ferroptosis[1]. one time/day for two weeks Experimental Results: Inhibition of GPX4, SLC7A11 and FTH1 expression levels, indicating induction of ferroptosis. Resulting in little change in weight. |
| References |
| Molecular Formula |
C23H19N5O4
|
|---|---|
| Molecular Weight |
429.428064584732
|
| Exact Mass |
429.143
|
| CAS # |
2740522-79-4
|
| Related CAS # |
W1131 TFA
|
| PubChem CID |
162371933
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
732
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([N+]([O-])=O)=CC=C1C(NC1=CC=C(C2N3C(=NC=2)C=C(C2=CCNCC2)C=C3)C=C1)=O
|
| InChi Key |
CMVDOFFRPTYZID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H19N5O4/c29-23(20-5-6-22(32-20)28(30)31)26-18-3-1-16(2-4-18)19-14-25-21-13-17(9-12-27(19)21)15-7-10-24-11-8-15/h1-7,9,12-14,24H,8,10-11H2,(H,26,29)
|
| Chemical Name |
5-nitro-N-[4-[7-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]furan-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~232.9 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3287 mL | 11.6433 mL | 23.2867 mL | |
| 5 mM | 0.4657 mL | 2.3287 mL | 4.6573 mL | |
| 10 mM | 0.2329 mL | 1.1643 mL | 2.3287 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
